PCS
NBIX icon

Private Client Services’s Neurocrine Biosciences NBIX Stock Holding History

Private Client Services’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$373K Sell
2,629
-527
-17% -$84.7K 0.1% 153
2026
Q2 		$532K Sell
3,156
-9,310
-75% -$1.38M 0.14% 128
2026
Q1 		$1.64M Buy
+12,466
New +$1.65M 0.49% 48

Other funds holding NBIX

CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
ACM
Argent Capital Management St Louis, Missouri $3.14B AUM 31.36% 1-Year Est. Return
RSC
Red Spruce Capital Berwyn, Pennsylvania $283M AUM 29.49% 1-Year Est. Return
MNBTD
Moody National Bank Trust Division Galveston, Texas $1.21B AUM 28.25% 1-Year Est. Return
JWS
Juncture Wealth Strategies Scottsdale, Arizona $390M AUM 19.15% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
WWM
Whalen Wealth Management Las Vegas, Nevada $234M AUM 28.06% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
CCAL
City Center Advisors LLC Troy, Michigan $131M AUM 24.02% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 19.15% 1-Year Est. Return

Private Client Services's NBIX Position: Q3 2026 in Review

Private Client Services reduced its Neurocrine Biosciences (NBIX) stake by 17% in Q3 2026, selling an estimated $84.7K and leaving 2,629 shares worth $373K. The position accounts for 0.1% of the portfolio, ranked #153.

Private Client Services first reported a position in NBIX in Q1 2026 and has held it in 3 quarters since. The position peaked at $1.64M in Q1 2026. 21 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • Private Client Services held 2,629 shares of Neurocrine Biosciences worth $373K as of Q3 2026.
  • Private Client Services sold 527 Neurocrine Biosciences shares in Q3 2026, an estimated $84.7K.
  • Neurocrine Biosciences made up 0.1% of Private Client Services's portfolio in Q3 2026, its #153 holding.
  • Private Client Services first reported a position in Neurocrine Biosciences in Q1 2026 and has held it in 3 quarters since.
  • Private Client Services's Neurocrine Biosciences position peaked at $1.64M in Q1 2026.
  • 21 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Private Client Services's 13F filing for Q3 2026, filed 2 Oct 2026.